We have started developing a modular digital engagement platform for public use, with input from key stakeholders in the ecosystem (e.g. researchers, healthcare providers, and advocacy organizations). Public involvement, awareness and outreach activities have also been initiated.
A 2-stage approach is being used to test and validate Digital Cognitive Assessments and Blood Based Biomarkers, starting with a pilot stage focused on assessing the feasibility and usability of DCAs, and continuing with larger-scale testing of both DCAs and BBMs, in alignment with implementation evaluation work. The protocol for the pilot stage and the BBMs protocol have been completed. In addition, the framework for the large-scale testing stage of both DCAs and BBMs has been laid out, aligning across all relevant work packages. We have also established the implementation evaluation framework including harmonization of variables and establishing the Community of Practice (CoP) process model and governance structure, including framework for documentation and sharing of implementation learnings.
The first version of the Data Map for existing data has been completed, and we have created an initial Data Flow overview that tracks how data at this stage of the project is currently being collected, shared, and managed. Development and/or testing of predictive algorithms/models was conducted in parallel in existing observational cohorts (early risk and disease detection) and multidomain lifestyle-based intervention RCTs (response to intervention).
To ensure the quality of the AD-RIDDLE toolbox and to provide ethical guidance on potential socio-ethical implications of the project, a review of relevant literature was conducted to explore the ethical concerns linked to the development and implementation of population-level health screening approaches for AD/dementia risk. In combination with the Public Involvement work and a policy and practice review, the findings will inform the AD-RIDDLE toolbox design.
A scoping review of funding models was conducted, with emphasis on health impact bonds in health intervention programs. A health economic model for dementia prevention has also been developed by integrating the effects of cardiovascular disease.
Furthermore, we have conducted an assessment of health technology assessment (HTA) evidence requirements across Europe relevant for the AD-RIDDLE toolbox development, and a HTA Standing Forum was set up.
Work has begun on the sustainability workstream to identify, prioritise and select the project assets in advance, with the aim of maximising the sustainability of AD-RIDDLE and its impact on the field.
